| 1.9 0.05 (2.7%) | 06-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.46  |
1-year : | 2.92 |
| Resists | First : | 2.11 |
Second : | 2.5 |
| Pivot price | 1.89 |
|||
| Supports | First : | 1.48 |
Second : | 1.23 |
| MAs | MA(5) : | 1.97 |
MA(20) : | 1.83 |
| MA(100) : | 1.76 |
MA(250) : | 1.63 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.3 |
D(3) : | 43 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 2.5 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LIFE ] has closed above bottom band by 42.2%. Bollinger Bands are 61.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.93 - 1.94 | 1.94 - 1.96 |
| Low: | 1.79 - 1.8 | 1.8 - 1.81 |
| Close: | 1.82 - 1.84 | 1.84 - 1.86 |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Wed, 02 Apr 2025
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
Tue, 18 Feb 2025
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation - Nasdaq
Mon, 03 Jun 2024
aTyr Pharma CEO Sanjay Shukla buys $36.1k in company stock - Investing.com
Mon, 03 Jun 2024
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” - GlobeNewswire
Sat, 03 Feb 2024
After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gain - Yahoo Finance
Fri, 03 Mar 2023
aTyr Pharma has a huge upside, says Roth Capital - Cantech Letter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 6.712e+007 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 383 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.808e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 79.1 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | 588000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -46.74 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 1.76 |
| Dividend | 0 |
| Forward Dividend | 343410 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|